deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02924376

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)

Sponsor: Incyte Corporation

Conditions Cholangiocarcinoma
Interventions Pemigatinib
Updated 30 times since 2017 Last updated: Aug 12, 2025 Started: Jan 16, 2017 Primary completion: Feb 1, 2022 Completion: Feb 1, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cholangiocarcinoma and is currently completed. Incyte Corporation leads this study, which shows 30 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~Jul 2020 · 6 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~May 2022 · 6 months · monthly snapshot~May 2022 – ~Mar 2023 · 10 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

30 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Mar 2023 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 25 earlier versions

  1. May 2022 — Mar 2023 [monthly]

    Completed PHASE2

  2. Nov 2021 — May 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Oct 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Jan 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  10. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  11. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  12. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

  13. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  14. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2

  15. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  16. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  17. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  18. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  19. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  20. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  21. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  22. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  23. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  24. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  25. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Corporation
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Anchorage, United States , Ann Arbor, United States , Arlington, United States , Aurora, United States , Avignon, France , Baltimore, United States , Bangkok, Thailand , Bangkoknoi, Thailand , Barcelona, Spain and 109 more locations